{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T18:19:33Z","timestamp":1783448373142,"version":"3.55.0"},"reference-count":25,"publisher":"Bioscientifica","issue":"6","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":222,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Subclinical hyperthyroidism (SHT), a low serum thyroid-stimulating hormone (TSH) and normal free thyroxine (FT4) concentration, has potential health implications, yet the epidemiology and factors influencing its natural course in a primary care setting remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate the incidence and natural course of SHT in primary care and assess guideline adherence to follow-up recommendations within Dutch primary care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using a retrospective cohort design in general practitioner data from the PHARMO Data Network in the Netherlands (2012\u20132021), patients with biochemically confirmed SHT were followed to assess progression to hyperthyroidism, recovery, or persistence. Adherence to the Dutch primary care SHT guideline was evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The SHT annual incidence was approximately 200 per 100,000 person-years. Among the 11,163 SHT patients, 47% recovered, 11% persisted, and 8% progressed to overt hyperthyroidism over a median follow-up of 5 years. Lower TSH (&amp;lt;0.1 mU\/L) and female sex were associated with lower odds of recovery (OR for TSH &amp;lt;0.1 mU\/L: 0.50, 95% CI: 0.43\u20130.58; OR for women: 0.82, 95% CI: 0.70\u20130.96) and higher odds of progression to overt hyperthyroidism (OR for TSH &amp;lt;0.1 mU\/L: 2.36, 95% CI: 1.97\u20132.83; OR for women: 1.69, 95% CI: 1.32\u20132.17). Guideline adherence evaluation showed that 33% received follow-up TSH measurement within 6 months, and 4% underwent TSH-receptor antibody testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study highlights that a small subset of SHT patients progress to overt hyperthyroidism. Factors increasing the odds for progression included lower baseline TSH and female sex. Our findings indicate a need for improved guideline adherence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/etj-25-0142","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T15:31:28Z","timestamp":1762443088000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-17","source":"Crossref","is-referenced-by-count":1,"title":["Natural course of subclinical hyperthyroidism in primary care in the Netherlands"],"prefix":"10.1530","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9989-0821","authenticated-orcid":true,"given":"Stan R","family":"Ursem","sequence":"first","affiliation":[{"name":"1"},{"name":"2"},{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy P J","family":"den Elzen","sequence":"additional","affiliation":[{"name":"2"},{"name":"4"},{"name":"5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3270-6641","authenticated-orcid":false,"given":"Jesse M","family":"van den Berg","sequence":"additional","affiliation":[{"name":"3"},{"name":"5"},{"name":"6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4994-2918","authenticated-orcid":true,"given":"Anita","family":"Boelen","sequence":"additional","affiliation":[{"name":"1"},{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra J M","family":"Elders","sequence":"additional","affiliation":[{"name":"3"},{"name":"5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Noordam","sequence":"additional","affiliation":[{"name":"7"},{"name":"8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6712-9955","authenticated-orcid":true,"given":"Annemieke C","family":"Heijboer","sequence":"additional","affiliation":[{"name":"1"},{"name":"2"},{"name":"9"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"2026070714015718700_bib1","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S0140-6736(11)60276-6","article-title":"Subclinical thyroid disease","volume":"379","author":"Cooper","year":"2012","journal-title":"Lancet"},{"key":"2026070714015718700_bib2","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2265.2009.03694.x","article-title":"How should we treat patients with low serum thyrotropin concentrations?","volume":"72","author":"Mitchell","year":"2010","journal-title":"Clin Endocrinol"},{"key":"2026070714015718700_bib3","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMcp1709318","article-title":"Subclinical hyperthyroidism","volume":"378","author":"Biondi","year":"2018","journal-title":"N Engl J Med"},{"key":"2026070714015718700_bib4","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1001\/archinternmed.2012.402","article-title":"Subclinical hyperthyroidism and the risk of coronary heart disease and mortality","volume":"172","author":"Collet","year":"2012","journal-title":"Arch Intern Med"},{"key":"2026070714015718700_bib5","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1161\/CIRCULATIONAHA.112.096024","article-title":"Subclinical thyroid dysfunction and the risk of heart failure events an individual participant data analysis from 6 prospective cohorts","volume":"126","author":"Gencer","year":"2012","journal-title":"Circulation"},{"key":"2026070714015718700_bib6","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jama.295.9.1033","article-title":"Thyroid status, cardiovascular risk, and mortality in older adults","volume":"295","author":"Cappola","year":"2006","journal-title":"JAMA"},{"key":"2026070714015718700_bib7","first-page":"710","article-title":"Subclinical hyperthyroidism: when to consider treatment","volume":"95","author":"Donangelo","year":"2017","journal-title":"Am Fam Physician"},{"key":"2026070714015718700_bib8","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000438750","article-title":"The 2015 European Thyroid Association Guidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism","volume":"4","author":"Biondi","year":"2015","journal-title":"Eur Thyroid J"},{"key":"2026070714015718700_bib9","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1210\/jc.2010-2693","article-title":"The thyroid epidemiology, audit, and research study (TEARS): Morbidity in patients with endogenous subclinical hyperthyroidism","volume":"96","author":"Vadiveloo","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070714015718700_bib10","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1001\/archinte.167.14.1533","article-title":"Serum thyrotropin measurements in the community: five-year follow-up in a large network of primary care physicians","volume":"167","author":"Meyerovitch","year":"2007","journal-title":"Arch Intern Med"},{"key":"2026070714015718700_bib11","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1365-2265.2010.03908.x","article-title":"Subclinical thyrotoxicosis in an outpatient population-predictors of outcome","volume":"74","author":"Schouten","year":"2011","journal-title":"Clin Endocrinol"},{"key":"2026070714015718700_bib12","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-24-0036","article-title":"A systematic review of subclinical hyperthyroidism guidelines: a remarkable range of recommendations","volume":"13","author":"Ursem","year":"2024","journal-title":"Eur Thyroid J"},{"key":"2026070714015718700_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/CLEP.S389598","article-title":"Completeness and representativeness of the PHARMO general practitioner (GP) data: a comparison with national statistics","volume":"15","author":"Overbeek","year":"2023","journal-title":"Clin Epidemiol"},{"key":"2026070714015718700_bib14","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.3758\/s13428-021-01750-y","article-title":"SOLOMON: a method for splitting a sample into equivalent subsamples in factor analysis","volume":"54","author":"Lorenzo-Seva","year":"2022","journal-title":"Behav Res Methods"},{"key":"2026070714015718700_bib15","article-title":"NHG-standaard schildklieraandoeningen (M31)","author":"Van Lieshout","year":"2013"},{"key":"2026070714015718700_bib16","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1210\/jc.2013-2409","article-title":"The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis","volume":"99","author":"Madariaga","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070714015718700_bib17","doi-asserted-by":"crossref","first-page":"R325","DOI":"10.1530\/EJE-16-0276","article-title":"Management of endocrine disease: subclinical thyrotoxicosis: prevalence, causes and choice of therapy","volume":"176","author":"Carl\u00e9","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"2026070714015718700_bib18","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1089\/thy.2019.0414","article-title":"Impact of a forced dose-equivalent levothyroxine brand switch on plasma thyrotropin: a cohort study","volume":"30","author":"Flinterman","year":"2020","journal-title":"Thyroid"},{"key":"2026070714015718700_bib19","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American Thyroid Association Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Am Thyroid Assoc"},{"key":"2026070714015718700_bib20","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/MAJ.0b013e318187e16d","article-title":"An analysis of the natural course of subclinical hyperthyroidism","volume":"337","author":"D\u00edez","year":"2009","journal-title":"Am J Med Sci"},{"key":"2026070714015718700_bib21","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3390\/biology11030394","article-title":"Epidemiology of hypothyroidism, hyperthyroidism and positive thyroid antibodies in the Croatian population","volume":"11","author":"Striki\u0107 \u0110ula","year":"2022","journal-title":"Biology"},{"key":"2026070714015718700_bib22","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1365-2265.2012.04345.x","article-title":"Serum thyrotrophin at baseline predicts the natural course of subclinical hyperthyroidism","volume":"77","author":"Das","year":"2012","journal-title":"Clin Endocrinol"},{"key":"2026070714015718700_bib23","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1365-2265.2007.03030.x","article-title":"The natural history of subclinical hyperthyroidism in patients below the age of 65 years","volume":"68","author":"Rosario","year":"2008","journal-title":"Clin Endocrinol"},{"key":"2026070714015718700_bib24","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1365-2265.2009.03696.x","article-title":"Natural history of subclinical hyperthyroidism in elderly patients with TSH between 0\u00b71 and 0\u00b74 mIU\/L: a prospective study","volume":"72","author":"Rosario","year":"2010","journal-title":"Clin Endocrinol"},{"key":"2026070714015718700_bib25","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-23-0123","article-title":"How low can we (reliably) go? A method comparison of TSH assays with a focus on low concentrations","volume":"12","author":"Ursem","year":"2023","journal-title":"Eur Thyroid J"}],"container-title":["European Thyroid Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/etj.bioscientifica.com\/view\/journals\/etj\/14\/6\/ETJ-25-0142.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/etj.bioscientifica.com\/downloadpdf\/journals\/etj\/14\/6\/ETJ-25-0142.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/doi\/10.1530\/ETJ-25-0142\/506914\/etj-25-0142.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/doi\/10.1530\/ETJ-25-0142\/506914\/etj-25-0142.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T18:02:08Z","timestamp":1783447328000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article\/14\/6\/e250142\/75673\/Natural-course-of-subclinical-hyperthyroidism-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1530\/etj-25-0142","relation":{},"ISSN":["2235-0802","2235-0640"],"issn-type":[{"value":"2235-0802","type":"electronic"},{"value":"2235-0640","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"article-number":"e250142"}}